{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:00:38Z","timestamp":1788872438544,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.contraception.2011.11.001","type":"journal-article","created":{"date-parts":[[2012,3,6]],"date-time":"2012-03-06T06:53:25Z","timestamp":1331016805000},"page":"28-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Suppression of ovarian activity with a low-dose 21\/7-day regimen oral contraceptive containing ethinylestradiol 20 mcg\/drospirenone 3 mg in Japanese and Caucasian women"],"prefix":"10.1016","volume":"86","author":[{"given":"Yuzuru","family":"Anzai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Heger-Mahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilka","family":"Schellschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Marr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2011.11.001_bb0005","series-title":"Insights","first-page":"11","article-title":"New advances in contraception","author":"Shvarts","year":"2002"},{"key":"10.1016\/j.contraception.2011.11.001_bb0010","series-title":"Contraceptive technology, 18th revised ed.","first-page":"355","article-title":"Contraceptive efficacy","author":"Trussell","year":"2004"},{"key":"10.1016\/j.contraception.2011.11.001_bb0015","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0002-9378(98)70047-X","article-title":"Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons","volume":"179","author":"Rosenberg","year":"1998","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.11.001_bb0020","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0010-7824(95)00074-K","article-title":"Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation","volume":"51","author":"Rosenberg","year":"1995","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.11.001_bb0025","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.contraception.2004.05.013","article-title":"Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone","volume":"70","author":"Bachmann","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.11.001_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-4755-1-1","article-title":"Effectiveness and acceptability of progestogens in combined oral contraceptives \u2014 a systematic review","volume":"1","author":"Kulier","year":"2004","journal-title":"Reprod Health"},{"key":"10.1016\/j.contraception.2011.11.001_bb0035","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0010-7824(96)00195-3","article-title":"The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential","volume":"54","author":"Fuhrmann","year":"1996","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.11.001_bb0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0010-7824(00)00133-5","article-title":"Drospirenone: pharmacology and pharmacokinetics of a unique progestogen","volume":"62","author":"Krattenmacher","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.11.001_bb0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0010-7824(94)00015-O","article-title":"Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models","volume":"51","author":"Muhn","year":"1995","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.11.001_bb0050","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/13625180008500387","article-title":"A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel","volume":"5","author":"Foidart","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2011.11.001_bb0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/13625180008500375","article-title":"Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone","volume":"5","author":"Huber","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2011.11.001_bb0060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0010-7824(00)00083-4","article-title":"An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen","volume":"61","author":"Parsey","year":"2000","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.11.001_bb0065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/ejc.8.1.37.51","article-title":"Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms","volume":"8","author":"Apter","year":"2003","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2011.11.001_bb0070","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.contraception.2006.10.011","article-title":"The oral contraceptive containing 30 microg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study","volume":"75","author":"Fruzzetti","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.11.001_bb0075","first-page":"79","article-title":"Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life","volume":"48","author":"Borenstein","year":"2003","journal-title":"J Reprod Med"},{"key":"10.1016\/j.contraception.2011.11.001_bb0080","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.contraception.2005.10.016","article-title":"Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception","volume":"74","author":"Borges","year":"2006","journal-title":"Contraception"},{"issue":"Suppl 3","key":"10.1016\/j.contraception.2011.11.001_bb0085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/14730782.2000.12288988","article-title":"The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being","volume":"5","author":"Boschitsch","year":"2000","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2011.11.001_bb0090","first-page":"123","article-title":"Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment","volume":"74","author":"Thorneycroft","year":"2004","journal-title":"Cutis"},{"key":"10.1016\/j.contraception.2011.11.001_bb0095","first-page":"2","article-title":"The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea","volume":"69","author":"van Vloten","year":"2002","journal-title":"Cutis"},{"key":"10.1016\/j.contraception.2011.11.001_bb0100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00044011-200626030-00004","article-title":"Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20 microg and drospirenone 3 mg","volume":"26","author":"Cibula","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.contraception.2011.11.001_bb0105","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00024677-200605020-00005","article-title":"A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20 mug and drospirenone 3 mg with a 21-day regimen of ethinylestradiol 20 mug and desogestrel 150 mug","volume":"5","author":"Gruber","year":"2006","journal-title":"Treat Endocrinol"},{"key":"10.1016\/j.contraception.2011.11.001_bb0110","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0010-7824(93)90025-3","article-title":"Ultrasound evaluation of ovarian activity under oral contraceptives","volume":"47","author":"Hoogland","year":"1993","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.11.001_bb0115","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0010-7824(96)00183-7","article-title":"Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol","volume":"54","author":"Spona","year":"1996","journal-title":"Contraception"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411006330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411006330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:10:22Z","timestamp":1757880622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782411006330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0010782411006330"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2011.11.001","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suppression of ovarian activity with a low-dose 21\/7-day regimen oral contraceptive containing ethinylestradiol 20 mcg\/drospirenone 3 mg in Japanese and Caucasian women","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2011.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}